SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Journal of Cardiovascular Electrophysiology · 2024
DOI: 10.1111/jce.16344 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2024. Verfasst von Marco Valerio Mariani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Randomized Controlled Trials as Topic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 76 Literaturangaben.
Abstract (Originalsprache)
Introduction
Gliflozins are recommended as first‐line treatment in patients with heart failure and/or cardiovascular comorbidities and are demonstrated to reduce atrial fibrillation (AF) occurrence. However, it is not well known which gliflozin yields the larger cardioprotection in terms of AF occurrence reduction. Hence, we aimed to compare data regarding AF recurrence associated with different gliflozins.
Methods
An accurate search of online scientific libraries (from inception to June 1, 2023) was performed. Fifty‐nine studies were included in the meta‐analysis involving 108 026 patients, of whom 60 097 received gliflozins and 47 929 received placebo.
Results
Gliflozins provided a statistically significant reduction of AF occurrence relative to standard of care therapy in the overall population (relative risks [RR]: 0.8880, 95% CI: [0.8059; 0.9784], p = .0164) and in patients with diabetes and cardiorenal diseases (RR: 0.8352, 95% CI: [0.7219; 0.9663], p = .0155). Dapagliflozin significantly decreased AF occurrence as compared to placebo (0.7259 [0.6337; 0.8316], p < .0001) in the overall population, in patients with diabetes (RR: 0.2482, 95% CI: [0.0682; 0.9033], p = .0345), with diabetes associated with cardiorenal diseases (RR: 0.7192, 95% CI: [0.5679; 0.9110], p = .0063) and in the subanalysis including studies with follow‐up ≥1 year (RR: 0.7792, 95% CI: [0.6508; 0.9330], p = .0066). No significant differences in terms of AF protection were found among different gliflozins.
Conclusions
Dapagliflozin use was associated with significant reduction in AF risk as compared to placebo in overall population and patients with diabetes, whereas the use of other gliflozins did not significantly reduce AF occurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Rome, Italy.
- Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.
- Cardio Thoracic-Vascular and Organ Transplantation Surgery Department, Policlinico Umberto I Hospital, Rome, Italy.
ORCID-Profile: Marco Valerio Mariani, Domenico Laviola, Agostino Piro
Zitieren
APA
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D'Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., Vizza, C. D., & Lavalle, C. (2024). SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16344
Vancouver
Mariani MV, Manzi G, Pierucci N, Laviola D, Piro A, D'Amato A, et al. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16344
BibTeX
@article{Mariani2024,
author = {Mariani, Marco Valerio and Manzi, Giovanna and Pierucci, Nicola and Laviola, Domenico and Piro, Agostino and D'Amato, Andrea and Filomena, Domenico and Matteucci, Andrea and Severino, Paolo and Miraldi, Fabio and Vizza, Carmine Dario and Lavalle, Carlo},
title = {SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2024},
doi = {10.1111/jce.16344}
}
EUVIMED